Description
PBMCs from ulcerative colitis (UC) donors, isolated from leukopak material under cGMP-aligned conditions. Sourced from OrganaBio’s qualified, recallable donor pool with 14-marker infectious disease screening per 21 CFR 1271 and high-resolution NGS HLA typing. Disease-state PBMCs are supplied for research/discovery use only. Best fit: mucosal immune phenotyping, anti-integrin therapy mechanism work, and UC drug screening.
LeukoPAC-D-PBMC – Disease-State Cryopreserved Peripheral Blood Mononuclear Cells
LeukoPAC-D-PBMC delivers cryopreserved peripheral blood mononuclear cells from donors with documented disease conditions, collected under IRB-approved protocols. Disease-state PBMCs are essential for cell therapy development because manufacturing processes and assays optimized using healthy donor cells frequently fail to translate to cells from patients in the target population.
Ulcerative colitis donor PBMCs reflect the Th2-skewed mucosal immune dysregulation and anti-integrin therapy response phenotypes relevant to IBD drug development.
Why Disease-State PBMCs
Patients eligible for cell therapies have often been treated with multiple rounds of chemotherapy or other interventions, which can compromise T cell functionality and shift cellular phenotypes in ways that healthy donor controls do not capture. Process development on disease-state PBMCs allows manufacturing teams and assay developers to validate workflows against material that reflects the immune biology of the patient population they intend to treat.
Available Indications
This product is sourced from donors with documented ulcerative colitis (UC). OrganaBio’s disease-state donor pool spans 24 autoimmune and chronic inflammatory indications including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, Crohn’s disease, ulcerative colitis, psoriasis, and others. Contact the scientific team to confirm availability and lot status for your specific indication.
Documentation
Each sample is supported by comprehensive documentation including disease history, treatment background, inclusion and exclusion criteria compliance, and demographic profiles. Every lot ships with a Certificate of Analysis. Donors are enrolled under IRB-approved protocols with verified clinical diagnosis.
Configuration
Standard configuration: 1.0×10⁷ cells per vial, cryopreserved, stored at <−150°C in liquid nitrogen vapor phase. Custom cell counts, fresh format, and specific donor criteria available on request. Cells are for preclinical research use only and not for use in humans.
For background on disease-state donor samples in cell therapy development, see Why Disease-State Donor Samples Are Essential for Cell Therapy Development.
{“@context”:”https://schema.org”,”@type”:”Product”,”name”:”LeukoPAC-D-PBMC – Ulcerative Colitis Disease-State Cryopreserved PBMCs”,”description”:”Cryopreserved peripheral blood mononuclear cells from donors with documented ulcerative colitis (UC). Collected under IRB-approved protocols. Used for mucosal immune profiling, anti-integrin mechanism studies, and IBD drug screening.”,”brand”:{“@type”:”Brand”,”name”:”OrganaBio”},”manufacturer”:{“@type”:”Organization”,”name”:”OrganaBio”,”url”:”https://www.organabio.com”},”category”:”Disease-State Donor Material”,”sku”:”D-PBMC-UC-050″,”image”:”https://www.organabio.com/wp-content/uploads/2026/05/organabio-leukopac-d-pbmc-2026.png”,”offers”:{“@type”:”Offer”,”availability”:”https://schema.org/InStock”,”url”:”https://www.organabio.com/product/leukopak-d-pbmc-uc/”,”seller”:{“@type”:”Organization”,”name”:”OrganaBio”}}}
Frequently Asked Questions
What are Ulcerative Colitis PBMCs used for?
PBMCs from ulcerative colitis donors are used for mucosal immune phenotyping, anti-integrin therapy mechanism-of-action studies (vedolizumab class), IL-13 and IL-33 pathway characterization, and IBD comparative immunology.
What viability can I expect for cryopreserved Ulcerative Colitis PBMCs?
OrganaBio targets greater than 80% post-thaw viability for cryopreserved disease-state PBMCs. Lot-specific viability data is included in the Certificate of Analysis shipped with every order.
Are Ulcerative Colitis PBMC donors recallable?
Yes. OrganaBio maintains a recallable donor pool for disease-state indications. Donors can be re-collected for longitudinal studies under the same characterization profile. Availability is indication-dependent — contact the scientific team to confirm lot status and re-collection timing.
What HLA and KIR typing is provided for Ulcerative Colitis PBMC donors?
High-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP is performed on every donor. KIR genotyping is included in the standard donor characterization — a differentiator not standard at most competing suppliers.
Are Ulcerative Colitis PBMCs research use only or available at cGMP grade?
Disease-state donor material from OrganaBio is supplied for research and discovery use (RUO). For autoimmune cell therapy programs requiring GMP starting material, the clinical process uses the patient’s own apheresis — not research-use disease-state donors. Contact OrganaBio’s scientific team to discuss your specific program requirements.
{“@context”:”https://schema.org”,”@type”:”FAQPage”,”@id”:”https://www.organabio.com/product/leukopak-d-pbmc-uc/#faq”,”mainEntity”:[{“@type”:”Question”,”name”:”What are Ulcerative Colitis PBMCs used for?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”PBMCs from ulcerative colitis donors are used for mucosal immune phenotyping, anti-integrin therapy mechanism-of-action studies (vedolizumab class), IL-13 and IL-33 pathway characterization, and IBD comparative immunology.”}},{“@type”:”Question”,”name”:”What viability can I expect for cryopreserved Ulcerative Colitis PBMCs?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”OrganaBio targets greater than 80% post-thaw viability for disease-state PBMCs. Lot-specific viability data is included in the Certificate of Analysis.”}},{“@type”:”Question”,”name”:”Are Ulcerative Colitis PBMC donors recallable?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Yes. OrganaBio maintains a recallable donor pool. Donors can be re-collected for longitudinal studies. Availability is indication-dependent.”}},{“@type”:”Question”,”name”:”What HLA and KIR typing is provided?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”High-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP is performed on every donor. KIR genotyping is included as standard.”}},{“@type”:”Question”,”name”:”Are Ulcerative Colitis PBMCs research use only or available at cGMP grade?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Disease-state material is research/discovery use only (RUO). For autoimmune cell therapy GMP starting material, the clinical process uses the patient’s own apheresis.”}}]}




